BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dr. Mark W. Schwartz Joins Apthera, Inc. as President & CEO


1/8/2010 7:04:05 AM

Bookmark and Share

SCOTTSDALE, AZ--(Marketwire - 01/08/10) - Apthera, Inc. ("Apthera") today announced the appointments of Dr. Mark W. Schwartz to the position of President and Chief Executive Officer and Mr. Edward L. Jacobs to the Apthera Board as an independent director. Apthera also appointed Dr. Schwartz to the Board.

As President and CEO, Dr. Schwartz's primary responsibilities are to lead the Company's fundraising and partnering efforts and accelerate its product development activities. "We are very pleased to bring Dr. Schwartz onto the Apthera team. Mark brings to Apthera a proven track record of raising institutional capital and forming collaborative product development partnerships. Our objective will be to accelerate the development of Apthera's lead product, NeuVax?, an active specific immunotherapy for early-stage breast cancer," said Ira Z. Leiderman, Chairman of Apthera.

"I am excited to be appointed Apthera's President and CEO. Apthera represents a rare opportunity with its late-stage clinical program targeting women with triple-negative breast cancer. The FDA has accepted Apthera's Phase III Special Protocol Assessment (SPA) for NeuVax and the Company is entering discussions for a corporate partnership to fund this pivotal stage of clinical development," said Dr. Schwartz.

Edward Jacobs presently serves as the President and CEO of Ascalon International, Inc., a private oncology product development company. "We are excited that Mr. Jacobs has joined the Apthera board. Ed has spent his career in the field of oncology from the business side and brings to Apthera significant industry contacts and deal making expertise," stated Robert Kennedy, Chief Financial Officer.

About Apthera

Apthera, Inc. is a privately-held, Arizona-based biotechnology company developing a pipeline of peptide-based active specific immunotherapies for cancers that express HER2/neu, a well-validated and established oncology target. The Company's lead product, NeuVax, contains a patented peptide which has been documented over the past 8 years to elevate or boost pre-existing anti-cancer immunity in cancer patients. NeuVax's initial indication is for front-line adjuvant therapy of early-stage breast cancer patients who express HER2/neu but don't qualify for trastuzumab (Herceptin?) or lapatinib (Tykerb?). For more information about the Company visit www.apthera.com.

This news release contains forward-looking statements. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

Contact Apthera: Robert Kennedy CFO (480) 348-9705 Email Contact www.apthera.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES